AU2017223970B2 - Method and composition for treating cancer or skin lesion using a vaccine - Google Patents

Method and composition for treating cancer or skin lesion using a vaccine Download PDF

Info

Publication number
AU2017223970B2
AU2017223970B2 AU2017223970A AU2017223970A AU2017223970B2 AU 2017223970 B2 AU2017223970 B2 AU 2017223970B2 AU 2017223970 A AU2017223970 A AU 2017223970A AU 2017223970 A AU2017223970 A AU 2017223970A AU 2017223970 B2 AU2017223970 B2 AU 2017223970B2
Authority
AU
Australia
Prior art keywords
hpv
vaccine
cancer
dose
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017223970A
Other languages
English (en)
Other versions
AU2017223970A1 (en
Inventor
Tim Ioannides
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hpvvax LLC
Original Assignee
Hpvvax LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hpvvax LLC filed Critical Hpvvax LLC
Publication of AU2017223970A1 publication Critical patent/AU2017223970A1/en
Application granted granted Critical
Publication of AU2017223970B2 publication Critical patent/AU2017223970B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Anesthesiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
AU2017223970A 2016-02-27 2017-02-24 Method and composition for treating cancer or skin lesion using a vaccine Active AU2017223970B2 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201662300785P 2016-02-27 2016-02-27
US62/300,785 2016-02-27
US201662328487P 2016-04-27 2016-04-27
US62/328,487 2016-04-27
US201662338183P 2016-05-18 2016-05-18
US62/338,183 2016-05-18
US201762444576P 2017-01-10 2017-01-10
US62/444,576 2017-01-10
US201762455434P 2017-02-06 2017-02-06
US62/455,434 2017-02-06
PCT/US2017/019433 WO2017147475A1 (en) 2016-02-27 2017-02-24 Method and composition for treating cancer or skin lesion using a vaccine

Publications (2)

Publication Number Publication Date
AU2017223970A1 AU2017223970A1 (en) 2018-09-13
AU2017223970B2 true AU2017223970B2 (en) 2022-01-27

Family

ID=59686556

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017223970A Active AU2017223970B2 (en) 2016-02-27 2017-02-24 Method and composition for treating cancer or skin lesion using a vaccine

Country Status (16)

Country Link
EP (1) EP3419661A4 (enExample)
JP (3) JP2019506435A (enExample)
KR (1) KR102873848B1 (enExample)
CN (1) CN108883168A (enExample)
AU (1) AU2017223970B2 (enExample)
BR (1) BR112018067550A2 (enExample)
CA (1) CA3015519A1 (enExample)
CL (1) CL2018002438A1 (enExample)
CO (1) CO2018009205A2 (enExample)
HK (1) HK1256935A1 (enExample)
IL (1) IL261340B2 (enExample)
MX (1) MX2018010338A (enExample)
MY (1) MY194694A (enExample)
SG (1) SG11201807080UA (enExample)
WO (1) WO2017147475A1 (enExample)
ZA (1) ZA201805679B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021013069A1 (zh) * 2019-07-19 2021-01-28 神州细胞工程有限公司 嵌合的人乳头瘤病毒11型l1蛋白
FI4225351T1 (fi) * 2020-10-12 2023-10-20 Hpvvax Llc Koostumus ja menetelmä syövän hoitamiseksi käyttämällä rokotetta ensimmäisenä terapeuttisesti aktiivisena ainesosana yhdessä toisen aktiivisen ainesosan kanssa
EP4611770A1 (en) * 2022-10-31 2025-09-10 Pyrojas Inc. Immunotherapy compositions and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010120266A1 (en) * 2009-04-13 2010-10-21 Inserm, Institut National De La Sante Et De La Recherche Medicale Hpv particles and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
CN101890160B (zh) * 2009-04-28 2014-06-18 北京康乐卫士生物技术有限公司 多价重组人乳头瘤病毒疫苗及其应用
EA022213B1 (ru) * 2009-06-25 2015-11-30 Глаксосмитклайн Байолоджикалс С.А. Новые конструкции белка вируса папилломы человека (hpv) и их применение в предупреждении заболевания, вызываемого hpv
CA2838387A1 (en) * 2011-06-06 2012-12-13 Chevron Phillips Chemical Company Lp Use of metallocene compounds for cancer treatment
US20130064849A1 (en) * 2011-07-14 2013-03-14 The Board Of Regents Of The University Of Texas Methods to treat and prevent cardiovascular disease using human papillomavirus vaccines
JP2015514696A (ja) * 2012-03-18 2015-05-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ヒト・パピローマウイルスに対するワクチン接種方法
US20130251782A1 (en) * 2012-03-22 2013-09-26 Leo Laboratories Limited Topical application of ingenol mebutate with occlusion
US20140275082A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CA2927126A1 (en) * 2013-10-13 2015-04-16 The Board Of Trustees Of The University Of Arkansas Human papilloma virus therapeutic vaccine
CN120939216A (zh) * 2014-01-13 2025-11-14 贝勒研究院 抗hpv和hpv相关的疾病的新疫苗
SG11201703262UA (en) * 2014-10-24 2017-05-30 Hpvvax Llc Cancer and skin lesion treatment

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010120266A1 (en) * 2009-04-13 2010-10-21 Inserm, Institut National De La Sante Et De La Recherche Medicale Hpv particles and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DANIELA LEDIC DRVAR ET AL, "Human papillomavirus status in extragenital nonmelanoma skin cancers", CLINICS IN DERMATOLOGY., US, (2014-03-01), vol. 32, no. 2, doi:10.1016/j.clindermatol.2013.08.009, ISSN 0738-081X, pages 248 - 252 *
MEGAN N. LANDIS ET AL, "Recalcitrant plantar warts treated with recombinant quadrivalent human papillomavirus vaccine", JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY., US, (2012-08-01), vol. 67, no. 2, pages e73 - e74 *

Also Published As

Publication number Publication date
KR20180112043A (ko) 2018-10-11
CO2018009205A2 (es) 2018-09-20
MX2018010338A (es) 2018-11-09
AU2017223970A1 (en) 2018-09-13
JP7732784B2 (ja) 2025-09-02
JP2023110038A (ja) 2023-08-08
IL261340B1 (en) 2023-03-01
CA3015519A1 (en) 2017-08-31
MY194694A (en) 2022-12-15
JP2021155448A (ja) 2021-10-07
WO2017147475A1 (en) 2017-08-31
BR112018067550A2 (pt) 2019-10-01
JP2019506435A (ja) 2019-03-07
IL261340B2 (en) 2023-07-01
CL2018002438A1 (es) 2019-01-04
ZA201805679B (en) 2019-11-27
HK1256935A1 (zh) 2019-10-04
KR102873848B1 (ko) 2025-10-17
CN108883168A (zh) 2018-11-23
EP3419661A1 (en) 2019-01-02
EP3419661A4 (en) 2019-10-23
SG11201807080UA (en) 2018-09-27
IL261340A (en) 2018-11-29

Similar Documents

Publication Publication Date Title
EP3273955B1 (en) Treatment of respiratory diseases
JP7732784B2 (ja) ワクチンを使用して癌または皮膚病変を治療するための方法および組成物
US20240226213A1 (en) Treatment of Warts
US10799574B2 (en) Method and composition for treating cancer or skin lesion using a vaccine
US11813329B2 (en) Method and composition for treating cancer or skin lesion using a vaccine
AU2021360676B2 (en) Composition and method for treating cancer using a vaccine as a first therapueutic active ingredient in combination with a second active ingredient
CN115463118A (zh) 和厚朴酚在制备治疗或预防毛细血管瘤的药物中的用途
CA3219273A1 (en) Use of 5-nitro-8-hydroxyquinoline
US20230414741A1 (en) Method and compositon for treating cancer using a vaccine
US20220105082A1 (en) New formulations containing leukotriene receptor antagonists
WO2022206086A1 (zh) 靶向灭活疱疹病毒膏贴药物组合物及其制备方法与应用
CN109939223B (zh) 一种白介素2在制备用于治疗寻常型天疱疮口腔糜烂药物的应用
RU2681546C1 (ru) Способ экстренной профилактики клещевого вирусного энцефалита
WO2022264097A1 (en) Pharmaceutical composition of anti-tumour necrosis factor (anti-tnf) agent for management of infectious diseases caused by coronaviruses
US20210346459A1 (en) Application of Dalargin for the prevention of VRIs and prevention of the development of complications during VRIs
HK40058742A (en) Treatment of respiratory diseases
HK40059876A (en) Treatment of respiratory diseases
EP4522153A1 (en) Methods of treatment using a dual specificity tyrosine-phosphorylation-regulated kinase 1a (dyrk1a) inhibitor
TWI418347B (zh) 治療疱疹病毒感染的方法
HK40055016A (en) Treatment of warts
CN107308145A (zh) 苯乙双胍作为皮肤抗炎制剂的用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)